Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The AC-065A302 (GRIPHON) study is an event-driven Phase 3 study to demonstrate the effect of
selexipag on time to first morbidity or mortality event in patients with pulmonary arterial
hypertension.